Mizuho lowered the firm’s price target on Inspire Medical to $300 from $380 and keeps a Buy rating on the shares. The analyst lower targets on several medical technology names ahead of the Q3 earnings season to reflect inputs from hospital/physician surveys and key opinion leader channel checks. The target drops account for the sharp intra-quarter contraction driven in part by GLP-1 risk concerns, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on INSP:
- Inspire Medical initiated with a Market Perform at Leerink
- Inspire Medical price target lowered to $260 from $340 at Truist
- Inspire Medical Systems, Inc. to Report Third Quarter 2023 Financial Results on November 7, 2023
- Inspire Medical Systems, Inc. Announces Events at International Surgical Sleep Society and American Academy of Otolaryngology – Head and Neck Surgery Meetings
- Weight-loss drugs are bad news for medtech makers, Barron’s says